Targeting HMGB1 inhibits bladder cancer cells bioactivity by lentivirusmediated RNA interference

Neoplasma

Volumn 61, Issue 6, 2014, Pages 638-646

  Wang, W ^a   Zhu, H ^a   Zhang, H ^a   Zhang, L ^a   Ding, Q ^a   Jiang, H ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Bladder cancer; HMGB1; Proliferation; RNA interference

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA; PYRROLIDINE DITHIOCARBAMATE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER INHIBITION; CARCINOGENICITY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRUS INFECTION; MALE; MOUSE; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RNA EXTRACTION; RNA INTERFERENCE; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; GENETICS; LENTIVIRINAE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ANIMALS; CELL LINE, TUMOR; HMGB1 PROTEIN; HUMANS; LENTIVIRUS; MALE; MICE; MICE, INBRED BALB C; RNA INTERFERENCE; URINARY BLADDER NEOPLASMS;

EID: 84910671824     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_079     Document Type: Article

References (30)

1. SIEGEL R, NAISHADHAM D, and JEMAL A. Cancer statistics, 2013. CA CANCER J CLIN 2013; 63: 11-30. http://dx.doi.org/10.3322/caac.21166
2. CHEN W, ZHENG R, ZHANG S, ZHAO P, LI G, et al. Report of incidence and mortality in China cancer registries, 2009. Chinese journal of cancer research 2013; 25: 10-21.
3. VIANELLO A, COSTANTINI E, DEL ZINGARO M, BINI V, HERR HW, et al. Repeated white light transurethral resection of the bladder in nonmuscle-invasive urothelial bladder cancers: systematic review and meta-analysis. J Endourol 2011; 25: 1703-12. http://dx.doi.org/10.1089/end.2011.0081
4. KU JH and LERNER SP. Strategies to prevent progression of high-risk bladder cancer at initial diagnosis. Curr Opin Urol 2012; 22: 405-14. http://dx.doi.org/10.1097/MOU.0b013e328356adff
5. VISHNU P, MATHEW J, AND TAN WW. Current therapeutic strategies for invasive and metastatic bladder cancer. OncoTargets and Therapy 2011; 4: 97-113.
6. GAKIS G, SCHWENTNER C, TODENHOFER T, and STENZL A. Current status of molecular markers for prognostication and outcome in invasive bladder cancer. BJU Int 2012; 110: 233-7. http://dx.doi.org/10.1111/j.1464-410X.2011.10839.x
7. NAGLOVA H and BUCOVA M. HMGB1 and its physiological and pathological roles. Bratisl Lek Listy 2012; 113: 163-71.
8. AGRESTI A and BIANCHI ME. HMGB proteins and gene expression. Curr Opin Genet Dev 2003; 13: 170-8. http://dx.doi.org/10.1016/S0959-437X(03)00023-6
9. SIMS GP, ROWE DC, RIETDIJK ST, HERBST R, and COYLE AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-388. http://dx.doi.org/10.1146/annurev.immunol.021908.132603
10. WANG H, BLOOM O, ZHANG M, VISHNUBHAKAT JM, OMBRELLINO M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-51. http://dx.doi.org/10.1126/science.285.5425.248
11. CHOW MT, MOLLER A, AND SMYTH MJ. Inflammation and immune surveillance in cancer. Semin Cancer Biol 2012; 22: 23-32. http://dx.doi.org/10.1016/j.semcancer.2011.12.004
12. KOSTOVA N, ZLATEVA S, UGRINOVA I, and PASHEVA E. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 2010; 337: 251-258. http://dx.doi.org/10.1007/s11010-009-0305-0
13. SHARMA A, RAY R, AND RAJESWARI MR. Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Invest 2008; 26: 843-51. http://dx.doi.org/10.1080/07357900801954210
14. GNANASEKAR M, THIRUGNANAM S, and RAMASWAMY K. Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol 2009; 34: 425-431.
15. YAO X, ZHAO G, YANG H, HONG X, BIE L, et al. Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 2010; 136: 677-84. http://dx.doi.org/10.1007/s00432-009-0706-1
16. JIAO Y, WANG HC, and FAN SJ. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 2007; 28: 1957-67. http://dx.doi.org/10.1111/j.1745-7254.2007.00669.x
17. YANG GL, ZHANG LH, BO JJ, HUO XJ, CHEN HG, et al. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol 2012; 106: 57-61. http://dx.doi.org/10.1002/jso.23040
18. WANG W, JIANG HW, ZHU HC, ZHANG H, GONG J, et al. Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma. Oncol Lett 2012
19. PFAFFL MW, HORGAN GW, and DEMPFLE L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in realtime PCR. Nucleic Acids Res 2002; 30: e36. http://dx.doi.org/10.1093/nar/30.9.e36
20. LOHELA M, BRY M, TAMMELA T, and ALITALO K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009; 21: 154-165. http://dx.doi.org/10.1016/j.ceb.2008.12.012
21. DIDONATO JA, MERCURIO F, and KARIN M. NF-kappaB and the link between inflammation and cancer. Immunol Rev 2012; 246: 379-400. http://dx.doi.org/10.1111/j.1600-065X.2012.01099.x
22. TANG D, KANG R, ZEH HJ 3RD, and LOTZE MT. Highmobility group box 1, oxidative stress, and disease. Antioxid Redox Signal 2011; 14: 1315-1335. http://dx.doi.org/10.1089/ars.2010.3356
23. KRYNETSKAIA NF, PHADKE MS, JADHAV SH, AND KRYNETSKIY EY. Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther 2009; 8: 864-72. http://dx.doi.org/10.1158/1535-7163.MCT-08-0695
24. TANG D, KANG R, ZEH HJ 3RD, and LOTZE MT. High-mobility group box 1 and cancer. Biochim Biophys Acta 2010; 1799: 131-140. http://dx.doi.org/10.1016/j.bbagrm.2009.11.014
25. VAN BEIJNUM JR, BUURMAN WA, AND GRIFFIOEN AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008; 11: 91-9. http://dx.doi.org/10.1007/s10456-008-9093-5
26. BALDWIN AS. Regulation of cell death and autophagy by IKK and NF-kappaB: critical mechanisms in immune function and cancer. Immunol Rev 2012; 246: 327-345. http://dx.doi.org/10.1111/j.1600-065X.2012.01095.x
27. HALLAM S, Escorcio-Correia M, SOPER R, SCHULTHEISS A, and HAGEMANN T. Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB. J Pathol 2009; 219: 143-152. http://dx.doi.org/10.1002/path.2602
28. ZHU C, QI X, CHEN Y, SUN B, DAI Y, et al. PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1induced VEGF-C upregulation in breast cancer. J Cancer Res Clin Oncol 2011; 137: 1587-1594. http://dx.doi.org/10.1007/s00432-011-1049-2
29. JIANG W, WANG Z, LI X, LI J, HUANG Y, et al. Reduced high-mobility group box 1 expression induced by RNA interference inhibits the bioactivity of hepatocellular carcinoma cell line HCCLM3. Dig Dis Sci 2012; 57: 92-98. http://dx.doi.org/10.1007/s10620-011-1944-z
30. FUJIOKA S, SON K, ONDA S, SCHMIDT C, SCRABAS GM, et al. Desensitization of NFkappaB for overcoming chemoresistance of pancreatic cancer cells to TNF-alpha or paclitaxel. Anticancer Res 2012; 32: 4813-4821.